Ischemia Clinical Trial
— RAVE2Official title:
A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
Status | Terminated |
Enrollment | 8 |
Est. completion date | |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects will be eligible if the following criteria are met: - Ability to provide written informed consent and comply with study assessments for the full duration of the study - Age > 18 years - For patients previously treated with ITV ranibizumab (Cohort 1): - 6 or more intravitreal injections of ranibizumab with presence of persistent edema after a minimum of 6 ranibizumab injections followed in RAVE 1. - For treatment naïve (Cohort 2): - Ischemic CRVO within 3 months of enrollment as per the following inclusion criteria Three of the following clinical tests must be present to demonstrate ischemic CRVO: - VA 20/200 or worse - RAPD 0.9 LU or worse - Loss of 1-2e isopter on Goldmann Visual field (Kwon et al. 2001) - ERG demonstrating b wave amplitude less than 60% of A wave - Capillary nonperfusion greater than 50 DA Exclusion Criteria: - Subjects who meet any of the following criteria will be excluded from this study: - IOP over 30 mm Hg - Any previous retinal laser photocoagulation to the study eye in treatment naive - Any previous intravitreal injection in study eye (triamcinolone or other) in treatment naive - Any previous vitrectomy in study eye (posterior or anterior associated with vitreous loss in cataract surgery) - Intracapsular cataract extraction (posterior capsule needs to be present) - Previous history of retinal detachment in study eye - Any previous radiation treatments to head/ neck - Inability to assess iris neovascularization (corneal opacity precluding gonioscopy) - Significant cardiovascular disease or cancer that would prevent follow-up visits or completion of the 12 month study - Significant diabetic retinopathy in the fellow eye (diabetic macular edema, proliferative diabetic retinopathy, or high-risk non-proliferative diabetic retinopathy) - Pregnancy (positive pregnancy test) - Participation in another simultaneous medical investigator or trial - Ocular disorders in the study eye that may confound interpretation of study results, including retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., DME AMD, ocular histoplasmosis, or pathologic myopia) - Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the study period - Aphakia or absence of the posterior capsule in the study eye - Previous violation of the posterior capsule is also excluded unless it occurred as a result of YAG laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation - History of idiopathic or autoimmune uveitis in either eye - Structural damage to the center of the macula in the study eye preexisting to CRVO likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s) - Vitreomacular traction or epiretinal membrane in the study eye evident biomicroscopically or by OCT - Ocular inflammation (including trace or above) in the study eye - Infectious blepharitis, keratitis, scleritis, or conjunctivitis (in either eye) or current treatment for serious systemic infection - Spherical equivalent of the refractive error in the study eye of more than -8 diopters myopia (For patients who have had refractive or cataract surgery in the study eye, pre-operative spherical equivalent refractive error of more than -8 diopters myopia is not allowed) Systemic Conditions - Uncontrolled Blood pressure exceeding diastolic pressure of 100 mm Hg (sitting) during the screening period - Uncontrolled diabetes mellitus - Renal failure requiring dialysis or renal transplant - Pregnancy (positive pregnancy test) or lactation - Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. - Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated - Participation in another simultaneous medical investigation or trial - History of other disease, metabolic dysfunction, physical examination finding, or other findings giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or render the subject at high risk from treatment complications Other - History of allergy to fluorescein, not amenable to treatment - Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed and graded by the central reading center - Inability to comply with study or follow up procedures - History of allergy to humanized antibodies or any component of the ranibizumab formulation |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Retina Consultants of Houston | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
David M. Brown, M.D. | Genentech, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean change from baseline in ETDRS BCVA at 6, 9, and 12 months. | 12 months. | No | |
Secondary | Incidence and severity of adverse events (ocular and non-ocular). | 12 months | Yes | |
Secondary | Percent of patients that develop neovascularization of the iris, optic nerve and/or elsewhere. | 12 months | No | |
Secondary | Mean change in Central Foveal Volume on High Resolution OCT at each visit. | 12 months | No | |
Secondary | Changes in electroretinography (ERG) at 12 months from baseline. | 12 months | No | |
Secondary | VEGF, other cytokines and ranibizumab levels in aqueous and serum samples at baseline, quarterly and prior each additional intravitreal injection. | 12 months | No | |
Secondary | Changes, by disc areas, of capillary non-perfusion in the periphery (evaluated by wide-field fluorescein angiography) at 3, 6, 9 and 12 months from baseline. | 12 months | No | |
Secondary | Goldman Visual Field changes at 6 and 12 months from baseline | 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05443061 -
Subcutaneous Nitroglycerin to Prevent Radial Artery Occlusion in Children
|
N/A | |
Recruiting |
NCT05158257 -
Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity
|
N/A | |
Recruiting |
NCT06006975 -
Early Warning of Delayed Cerebral Ischemia
|
||
Completed |
NCT02758847 -
Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty
|
N/A | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT02557282 -
CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol
|
||
Enrolling by invitation |
NCT02033681 -
Optimal Time Delay of Epinephrine Injection With "One-per-mil" Tumescent Solution
|
N/A | |
Completed |
NCT01608035 -
Sciatic Perineural Versus Stump Catheter for Below Knee Amputation
|
Phase 0 | |
Active, not recruiting |
NCT01518842 -
Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy
|
N/A | |
Completed |
NCT01625832 -
Effects of Coronary Sinus Occlusion on Myocardial Ischemia (Pilot Study)
|
N/A | |
Active, not recruiting |
NCT01281241 -
Study on Mechanical and Electrical Alternans
|
N/A | |
Completed |
NCT00778323 -
Clinical Trial of Remote Preconditioning in Patients Undergoing Cervical Decompression Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT00371371 -
Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)
|
Phase 1/Phase 2 | |
Terminated |
NCT00760708 -
Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
|
||
Not yet recruiting |
NCT06039748 -
Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
|
||
Completed |
NCT04879875 -
New Method for Real-time Detection of Tissue Ischemia (ISCALERT)
|
N/A | |
Completed |
NCT00526474 -
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
|
Phase 3 | |
Completed |
NCT03994822 -
pRESET for Occlusive Stroke Treatment
|
N/A | |
Completed |
NCT02910778 -
The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males
|
Phase 4 | |
Completed |
NCT02580149 -
The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment
|
Phase 4 |